OrbiMed

OrbiMed is a leading healthcare investment firm that invests in biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare services. It has over $18 billion in assets under management and operates globally across North America, Asia, and Europe. OrbiMed’s investment strategy is to identify and support innovative companies that can improve the lives of patients and create value for investors. It invests across all stages of development, from seed to growth to late-stage. It also provides non-dilutive structured debt capital and royalty monetization to commercial-stage healthcare companies. OrbiMed’s investment criteria vary depending on the sector, stage, and geography of the opportunity. However, some common factors that OrbiMed looks for are: A strong management team with relevant expertise and track record. A differentiated product or service with a clear competitive advantage and market potential. A compelling scientific rationale and clinical evidence for the product or service. A favorable regulatory and reimbursement environment. A reasonable valuation and attractive return potential. OrbiMed’s portfolio includes over 200 companies across various therapeutic areas, modalities, and geographies. Some of its notable portfolio companies are: ADARx Therapeutics, a biotechnology company developing messenger RNA targeting therapeutics. Biohaven Pharmaceuticals, a biopharmaceutical company focused on neurological diseases. Inari Medical, a medical device company specialized in venous disease. Twist Bioscience, a synthetic biology company that provides DNA writing and data storage solutions. OrbiMed’s benefits for its portfolio companies include: Access to a large and experienced team of investment professionals with diverse backgrounds and expertise in healthcare. Access to a global network of industry contacts, partners, and advisors. Access to capital across multiple funds and strategies. Active involvement and guidance in strategic, operational, and financial matters. Long-term commitment and support for growth and value creation.